Latest Tax Refunds News

Page 5 of 23
Marquee Resources has received a $549,122 R&D tax refund, adding non-dilutive cash ahead of planned drilling at its Yindi Lithium and Gold Project in Western Australia. The filing improves near-term financial flexibility but does not disclose the company’s post-refund cash balance or drilling budget.
Maxwell Dee
Maxwell Dee
17 Sept 2026
Michael Hill International reported a 1.9% revenue increase to $655.7 million in FY26, with comparable EBIT up 57% to $24 million and net profit soaring 376%. The company restored dividends and announced a Chair succession.
Logan Eniac
Logan Eniac
28 Aug 2026
Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.
Ada Torres
Ada Torres
27 Aug 2026
WAM Research’s FY2026 investment portfolio dropped 18%, dragging the company to a $28 million net loss. Despite underperformance, the LIC sustains its 10 cents per share dividend, backed by strong reserves and franking credits.
Claire Turing
Claire Turing
24 Aug 2026
Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.
Ada Torres
Ada Torres
31 July 2026
Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.
Ada Torres
Ada Torres
30 July 2026
Miramar Resources has doubled its gold Exploration Target at the Gidji JV near Kalgoorlie and completed its first drilling program at Chain Pool in over 60 years, while finalising the sale of Randalls Project and securing government grants to fund ongoing exploration.
Maxwell Dee
Maxwell Dee
30 July 2026
PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.
Ada Torres
Ada Torres
29 July 2026
Iluka Resources reported a rebound in zircon sales and prices in Q2 2026, while advancing its Eneabba rare earths refinery to nearly 60% completion and securing a key rare earths offtake deal.
Maxwell Dee
Maxwell Dee
28 July 2026
Australian Gold and Copper Ltd (ASX: AGC) has completed the second tranche of its $5 million placement, received a nearly $1 million R&D tax refund, and finalized the acquisition of the drill-ready Junee gold project in NSW.
Maxwell Dee
Maxwell Dee
23 July 2026
PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.
Ada Torres
Ada Torres
22 July 2026
Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.
Ada Torres
Ada Torres
22 July 2026

Browse the archive

Full archive